天津医药

天津医药 ›› 2022, Vol. 50 ›› Issue (5): 539-543.doi: 10.11958/20212207

• 药物临床观察 • 上一篇    下一篇

安罗替尼联合白蛋白结合型紫杉醇三线治疗非小细胞肺癌的临床疗效和安全性#br#

赵子龙1，张美云2，高辉2，杜伟2，巴雅尔2，吕艺华2△   

  1. 1内蒙古科技大学包头医学院第一附属医院呼吸与危重症科（邮编014010）；2包头市肿瘤医院肿瘤综合内科
  • 收稿日期:2021-09-24 修回日期:2022-01-09 出版日期:2022-05-15 发布日期:2022-07-04
  • 基金资助:
    白求恩•医学科学研究基金（B19096BT）

The clinical efficacy and safety of anlotinib and albumin-bound paclitaxel as the third-line therapy in patients with non-small cell lung cancer cancer

ZHAO Zilong1, ZHANG Meiyun2, GAO Hui2, DU Wei2, BA Yaer2, LYU Yihua2△   

  1. 1 Department of Respiratory and Critical Care, the First Affiliated Hospital of Baotou Medical College, Inner Mongolia University of Science and Technology, Baotou 014010, China; 2 Department of General Oncology, Baotou Tumor Hospital
  • Received:2021-09-24 Revised:2022-01-09 Published:2022-05-15 Online:2022-07-04

PDF (PC)

2276

摘要： 目的　探讨安罗替尼联合白蛋白结合型紫杉醇（Nab-P）三线治疗非小细胞肺癌（NSCLC）患者的疗效和安全性。方法　选取79例NSCLC患者作为研究对象，按照治疗方案分为对照组（36例）和研究组（43例），对照组采用Nab-P治疗，研究组采用安罗替尼联合Nab-P治疗。观察2组临床疗效，随访记录患者无进展生存期（PFS）、总生存期（OS）及不良反应；同时观察2组治疗前后血清血管内皮生长因子（VEGF）、癌胚抗原（CEA）和糖类抗原125（CA125）水平变化情况。结果　2组客观缓解率差异无统计学意义（16.28% vs. 8.33%，P＞0.05）；研究组疾病控制率高于对照组（76.74% vs. 52.78%，P＜0.05）。2组中位PFS分别为4个月和3个月（P＞0.05）；中位OS分别为9个月和7个月（P＜0.05）。治疗后，2组血清VEGF、CEA和CA125水平较治疗前均降低，且研究组低于对照组（P＜0.05）。治疗期间，2组不良反应发生率差异无统计学意义（P＞0.05）。结论　安罗替尼联合Nab-P三线治疗NSCLC具有较好的疗效，可有效降低血清VEGF、CEA和CA125水平，且安全性较好。

关键词: 白蛋白结合型紫杉醇；癌, 非小细胞肺；分子靶向治疗；血管内皮生长因子类；癌胚抗原；CA-125抗原；安罗替尼

Abstract: Objective　To investigate the clinical efficacy and safety of anlotinib and albumin-bound paclitaxel (Nab-P) as the third-line therapy in patients with non-small cell lung cancer (NSCLC). Methods　Seventy-nine patients with NSCLC were included in this study. According to the treatment plan, patients were divided into the control group (36 cases) and the study group (43 cases). The control group was treated with Nab-P, and the study group was treated with anlotinib combined with Nab-P. The clinical efficacy, progression free survival (PFS), overall survival (OS) and adverse reactions were observed in the two groups. The serum levels of vascular endothelial growth factor (VEGF), carcinoembryonic antigen (CEA) and carbohydrate antigen 125 (CA125) were observed before and after treatment in the two groups. Results　There was no significant difference in objective remission rate (ORR) between the two groups (16.28% vs. 8.33%，P＞0.05). The disease control rate (DCR) was significantly higher in the study group than that of the control group (76.74% vs. 52.78%, P＜0.05). The median PFS of the study group and the control group were 4 months and 3 months respectively (P＞0.05), and the median OS of the study group and the control group were 9 months and 7 months respectively (P＜0.05). After treatment, the serum levels of VEGF, CEA and CA125 were decreased than those of before treatment in the two groups (P＜0.05), and the serum levels of VEGF, CEA and CA125 were significantly lower in the study group than those in the control group (P＜0.05). During the treatment, there was no significant difference in the incidence of adverse reactions between the two groups (P＞0.05). Conclusion　Anlotinib combined with Nab-P as the third-line treatmenthas has good clinical efficacy in patients with NSCLC, which can effectively reduce serum VEGF, CEA and CA125 levels with good safety. 

Key words: albumin-bound paclitaxel, carcinoma, non-small-cell lung, molecular targeted therapy, vascular endothelial growth factors, carcinoembryonic antigen, CA-125 antigen, anlotinib

中图分类号: